BEDFORD, Mass., March 22, 2011 /PRNewswire/ — Instrumentation
Laboratory (IL) today announced total worldwide sales in 2010 of
Euro 474.2 million ($644.9 million US). This represents 11.5%
growth v. previous year in current, and 10.3% in local currencies.
In the Company’s two major business segments, Critical Care
and Hemostasis Diagnostics, worldwide growth in current currencies
was 13% (11.9% in local currencies) and 9.7% (8.9% in local
“We continued our robust growth trajectory in 2010, despite
continued economic pressure in the healthcare industry,” said Josep
Manent, Chief Executive Officer at IL. “Our products offer
customers tremendous time-and cost-efficiencies, key benefits in
these times of reduced hospital budgets and staff.”
Innovative new product offerings drove growth on both the
Hemostasis and Critical Care sides of the business.
In 2010, the Company launched the ACL TOP® 700 and ACL TOP
700 CTS Hemostasis Testing Systems. These analyzers joined
other members of the ACL TOP Family, including the ACL TOP 700 LAS
and ACL TOP 500 CTS, to offer hemostasis laboratories “Testing
Process Automation” and complete standardization.
Additionally, the new ACL AcuStar™ system, the first
automated, random-access chemiluminescent analyzer dedicated to
Hemostasis specialty testing, was launched in Europe. It is
exceptionally easy to use and offers maximum efficiency.
For the past eight years, the comprehensive HemosIL® line of
reagents has consistently dominated the market with the most
sophisticated assays for the diagnosis management and monitoring of
Hemostasis disorders. IL continued this trend in 2010 with
double digit growth in all key areas, most notably, with D-Dimer
and specialty assays, such as Thrombophilia Screening and Bleeding